- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Patent holdings for IPC class A61K 31/437
Total number of patents in this class: 10488
10-year publication summary
|
581
|
583
|
647
|
645
|
622
|
613
|
653
|
600
|
700
|
713
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4826 |
181 |
| Incyte Corporation | 1039 |
136 |
| F. Hoffmann-La Roche AG | 7937 |
134 |
| Takeda Pharmaceutical Company Limited | 2721 |
123 |
| Genentech, Inc. | 4016 |
122 |
| Novartis AG | 10612 |
109 |
| Janssen Pharmaceutica N.V. | 3358 |
106 |
| Boehringer Ingelheim International GmbH | 4636 |
100 |
| Merck Sharp & Dohme LLC | 3732 |
100 |
| Gilead Sciences, Inc. | 2106 |
95 |
| Merck Patent GmbH | 5752 |
85 |
| The Regents of the University of California | 20303 |
70 |
| Hoffmann-La Roche Inc. | 3546 |
69 |
| Bayer Pharma AG | 1048 |
69 |
| Abbvie Inc. | 1817 |
68 |
| Dana-Farber Cancer Institute, Inc. | 2626 |
67 |
| Pfizer Inc. | 3401 |
64 |
| Plexxikon Inc. | 148 |
59 |
| Taisho Pharmaceutical Co., Ltd. | 869 |
58 |
| Galapagos NV | 274 |
56 |
| Other owners | 8617 |